Ivonescimab’s median progression-free survival advantage over pembrolizumab, 11.14 months versus 5.82 months, was already striking when it first read out in May 2024. Now the harder number has arrived: a pre-specified interim analysis of the HARMONi-2 trial shows that overall survival advantage is also statistically significant and clinically meaningful, crossing a threshold that PFS data alone can never guarantee. That matters because OS is the endpoint that changes treatment guidelines, convinces payers, and, in the United States, determines whether the FDA’s pending biologics license application decision in November 2026 carries the weight Akeso needs it to carry.
The trial design underpins why this readout carries particular credibility. HARMONi-2 is a randomized, double-blind Phase III trial pitting ivonescimab directly against pembrolizumab in PD-L1-positive, locally advanced or metastatic NSCLC, the same population that pembrolizumab’s landmark first-line approval in 2016 was built on. Beating pembrolizumab head-to-head in OS, not merely in PFS, in that exact population is a genuinely different clinical argument. Ivonescimab’s mechanism, combining PD-1 blockade with VEGF inhibition in a single bispecific antibody, also resolves a long-standing practical constraint: conventional VEGF inhibition with bevacizumab has historically been contraindicated in squamous NSCLC due to pulmonary hemorrhage risk, yet the HARMONi-2 approval in China removed restrictions on VEGF-targeted use in squamous histology patients, expanding the eligible population meaningfully.
Akeso frames this as the fourth Phase III ivonescimab regimen to show statistically significant benefit in both OS and PFS across head-to-head trials versus PD-1/PD-L1 therapies, a pattern of replication that is harder to dismiss than a single trial result. The detailed OS numbers are not yet public, reserved for an upcoming international conference and peer-reviewed publication. That staged disclosure is standard but inconvenient: the magnitude of the hazard ratio and the maturity of the data are the two inputs that will determine how aggressively investigators, guideline committees, and payers recalibrate around this drug.
The single marker to track now is the November 2026 FDA BLA decision. The OS interim data almost certainly strengthens Akeso's regulatory package, but whether the agency accepts an interim analysis or demands more mature OS data before granting approval will define whether ivonescimab enters the U.S. market this year or waits for a fuller dataset.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
